ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer

Oncogenic KRAS mutations are major drivers of lung adenocarcinoma (LAC), yet the direct therapeutic targeting of KRAS has been problematic. Here, we reveal an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. In genetically engineered and xenograft (human cell line and patient‐d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO Mol Med
Main Authors: Saad, Mohamed I, Alhayyani, Sultan, McLeod, Louise, Yu, Liang, Alanazi, Mohammad, Deswaerte, Virginie, Tang, Ke, Jarde, Thierry, Smith, Julian A, Prodanovic, Zdenka, Tate, Michelle D, Balic, Jesse J, Watkins, D Neil, Cain, Jason E, Bozinovski, Steven, Algar, Elizabeth, Kohmoto, Tomohiro, Ebi, Hiromichi, Ferlin, Walter, Garbers, Christoph, Ruwanpura, Saleela, Sagi, Irit, Rose‐John, Stefan, Jenkins, Brendan J
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6460353/
https://ncbi.nlm.nih.gov/pubmed/30833304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201809976
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados